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K-ras is a member of ras gene family which is involved in cell survival, proliferation and differentiation. When a mutation 
occurs in ras gene, the activation of Ras proteins may be prolonged to induce oncogenesis. However, the relationship between 
K-ras mutation and clinical outcomes in pancreatic cancer patients treated with chemotherapy agents is still under debate. In 
this study, we constructed five pAcGFP1-C3 plasmids for different types of K-ras gene (WT, G12V, G12R, G12D, and G13D) 
and stably transfected human pancreatic cancer Bxpc-3 cells with these genes. The wild type and mutant clones showed a 
comparable growth and expression of K-Ras-GFP fusion protein. The expression of some K-ras mutations resulted in a re-
duced sensitivity to gefitinib, 5-FU, docetaxel and gemcitabine, while showed no effects on erlotinib or cisplatin. Moreover, 
compared with the wild type clone, K-Ras downstream signals (phospho-Akt and/or phospho-Erk) were increased in K-ras 
mutant clones. Interestingly, different types of K-ras mutation had non-identical K-Ras downstream signal activities and drug 
responses. Our results are the first to reveal the relationship between different K-ras mutation and drug sensitivities of these 
anti-cancer drugs in pancreatic cancer cells in vitro. 
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Pancreatic cancer is one of the most lethal human tumors 
[1], with a 5-year survival rate of less than 5%. The lack of 
effective treatments is still one of the greatest challenges in 
clinical chemotherapy. A good prognostic marker for pre-
dicting the treatment response may improve the chemo-
therapeutic efficacy.  
K-ras mutation is found in 90% pancreatic adenocarci-
nomas [2,3], and the most common mutations are located at 
codon 12, 13, or 61 as shown in the Sanger Registry 
(http://www.sanger.ac.uk). Considering its important role in 
cell survival and proliferation, K-ras has been extensively 
studied in recent years. Previous studies revealed that K-ras 
gene mutations cause excessive activation of K-RAS/ 
RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathways 
[4–9].  
There are increasing evidences showing that K-ras muta-
tional status can be regarded as a predictor of anti-epidermal 
growth factor (EGFR) monoclonal antibodies in colorectal 
cancer and non-small-cell lung cancer (NSCLC). Several 
recent phase 2 and 3 studies had demonstrated that mutant 
K-ras could be regarded as a predictor of poor response to 
panitumumab and cetuximab in colorectal cancer [10]. 
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However, the prognostic role of K-ras oncogenic mutation 
in patients who received cytotoxic chemotherapy is still 
under debate. Tsao et al. [11] reported that WT K-ras pa-
tients survived longer than K-ras mutant patients while 
treated with vinorelbine/cisplatin. Capelletti et al. [12] re-
ported that patients with K-ras mutations had a worse 
prognosis and derived less benefit form adjuvant car-
boplatin/paclitaxel. However, Pickard et al. [13] and Rosty 
et al. [14] both proved that mutant K-ras did not correlate 
with disease progression while treated with 5-FU/folinic 
acid.  
In the present study, we generated K-ras overexpressing 
clones with the four most common mutations (G12D, G12V, 
G12R and G13D) from human pancreatic cancer cell line 
Bxpc-3 with a wild-type (WT) egfr and K-ras. The chemo-
therapy sensitivity and its potential mechanism were also 
investigated in these clones to assess the predictive role of 
K-ras status in cytotoxic chemotherapy in pancreatic can-
cer. 
1  Materials and methods 
1.1  K-Ras-pAcGFP1-C3 plasmid construction 
The full sequence of K-ras gene carrying BamH I and Xho I 
sites, synthetized by Genewiz (Shanghai, China), was in-
serted into pAcGFP1-C3 vector (Clontech Laboratories, Inc, 
Mountain View, CA, USA) to construct K-Ras-pAcGFP1- 
C3. K-ras gene and pAcGFP1-C3 vector were digested by 
BamH I and Xho I restriction enzyme, followed by isolation 
and purification, and then ligated with T4 DNA ligase. Li-
gation products were transformed to E. coli DH5α, and then 
spread on 2×YT medium culture plate with kanamycin, 
which were cultured at 37°C overnight. Positive clones 
were picked up and screened by PCR, identified via digest-
ing by BamH I and Xho I restriction enzyme and sequencing 
the inserted fragments.  
1.2  Transfection and screening Bxpc-3 cells with stable 
expression of K-ras 
Bxpc-3 cells (Chinese Academy of Sciences, Shanghai, 
China) were cultured in RPMI1640 (Gibco, Carlsbad, CA, 
USA) supplemented with 10% FBS (Gibco) at 37°C in a 
humidified atmosphere of a 5% CO2. Bxpc-3 cells express 
wild-type (WT) egfr and K-ras, which can be obtained from 
the Wellcome Trust Sanger Institute Catalogue of Somatic 
Mutations in Cancer (COSMIC) website (http://www.sanger. 
ac.uk/cosmic/). 1×106 cells were seeded in a 12-well plate, 
and 12 h later, plasmids were transfected into cells with 
lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in 
RPMI1640 without FBS according to the manufacturer’s 
instructions. Forty-eight hours after transfection, the cells 
were diluted and selected in medium containing G418 (200 
μg mL1) for 14 d and then cloned using limiting dilution.  
The selected clones were screened by Western blot and 
mixed clones from at least three independent clones were 
used in the following experiments. 
1.3  Growth curves analysis 
Cell growth curve was used to analyze the effect of overex-
pression of K-ras on the proliferation of Bxpc-3 cells. The 
cells were seeded in a 96-well plate with a destiny of 5000 
cells each well. The cell number was detected every day by 
MTT assay as described before [15]. The absorbance was 
detected at 570 nm using a Multiskan GO microplate reader 
(Thermo Fisher Scientific Inc., Waltham, MA, USA).  
1.4  Drug sensitivity assay 
To compare the drug sensitivity in the established mutant 
clones, the following chemotherapy agents were used: erlo-
tinib (100 mmol L1 in DMSO), gefitinib (20 mmol L1 in 
DMSO), fluorouracil (5-FU, 100 mmol L1 in H2O), docet-
axel (100 mmol L1 in alcohol), gemcitabine (100 mmol L1 
in water) and cisplatin (100 mmol L1 in DMSO). Cells 
were seeded in 96-well plates as a density of 8000 cells per 
well and grew for 24 h. They were then exposed to various 
concentrations of chemotherapy agents for 48 h. The cyto-
toxicity effects of each drug on the growth of Bxpc-3 de-
rived K-ras mutant clones were evaluated using MTT assay. 
Data are presented as mean±SD of three independent ex-
periments.  
1.5  Apoptosis analysis 
Bxpc-3 cells were cultured in 6-well plates and treated with 
different chemotherapeutic agents for 48 h. Apoptotic cells 
were then identified by dual staining with FITC-conjugated 
with Annexin V and propidium iodide (PI) following the 
manufacturer’s protocol (BD biosciences, San Jose, CA, 
USA). Briefly, the collected cells were washed twice with 
PBS. Then, cells were incubated with Annexin V-FITC and 
then PI for 15 min in the dark at room temperature. Cells 
were then analyzed within 1 h using flow cytometry (FACS 
Calibur, Becton Dickinson, Franklin Lakes, NJ, USA) and a 
computer station running Cell-Quest software (Becton 
Dickinson, Franklin Lakes, NJ, USA). Meanwhile, stained 
cells were captured by a cooled CCD camera (Leica 
DMI4000D, Wetzlar, Germany) coupled to the microscope. 
1.6  Western blot analysis  
For Western blot analysis, cells were cultured with 
RPMI1640 with 0.1% FBS for 24 h, followed by stimulated 
by 10% FBS for 30 min. Protein was extracted using RIPA 
lysis buffer (Beyotime, Shanghai, China) with PMSF (final 
concentration 1 mg mL1; Beyotime) and Protease Inhibitor 
Cocktail Set III (final concentration 5 μL mL1; Merck  
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KGaA, Darmstadt, Germany), followed by boiling at 95°C 
for 10 min with SDS-PAGE loading buffer (Beyotime). The 
proteins were separated in a gel containing 10% acrylamide. 
After electrophoresis, the separated proteins were trans-
ferred to PVDF membranes using 200 mA for 30 min 
(K-Ras and GFP) or 60 min (β-Actin, Akt and Erk) accord-
ing to the molecular weight of proteins. The membranes 
were blocked with 5% BSA in Tris-buffered saline with 
0.1% Tween 20 for 1 h. After that, they were incubated with 
primary antibodies overnight at 4°C. The following anti-
bodies were used in our experiments: monoclonal mouse 
anti-phospho-Erk (Thr 202/Tyr 204), monoclonal rabbit 
anti-phospho-Akt (Ser473) antibodies (Cell Signaling 
Technology, Danvers, MA, USA); monoclonal mouse an-
ti-GFP for both GFP (27 kD) and K-Ras-GFP fusion protein 
(48 kD), monoclonal rabbit anti-Akt, monoclonal rabbit 
anti-Erk antibodies (Beyotime); monoclonal mouse an-
ti-K-Ras (Santa Cruz Biotechnology, Santa Cruz, CA, USA). 
After washing in TBST for four times, the membranes were 
incubated with secondary antibodies for 1 h. After that, the 
membranes were washed again in TBST for three times, 
followed by detecting using ECL plus (Beyotime). Images 
were captured with the Alpha Innotech imaging system (CA, 
USA).  
1.7  Statistical analysis 
Data are expressed as the mean±SD with three replicates at 
least. One-way ANOVA followed by LSD multiple com-
parison was used to compare cell response to drugs between 
different groups, and P<0.05 was considered to be signifi-
cant.  
2  Results 
2.1  Stable expression of different types of mutant 
K-ras in Bxpc-3 cells 
The different types of K-ras cDNA were successfully in-
serted into pAcGFP1-C3 plasmid (5.2 kb) identified by 
BamH I and Xho I digestion and electrophoresis. The ampli-
fication product of full-length K-ras gene (576 bp) from 
K-Ras-pAcGFP1-C3 plasmid was also verified by agarose 
gel.  
Plasmids with WT and four mutant K-ras genes were 
successfully transfected into human pancreatic cancer cell 
line Bxpc-3. Western blot analysis indicated that the K-Ras- 
pAcGFP1-C3 transfected cells expressed a 48 kD K-Ras- 
GFP fusion protein, while the vector transfected cells ex-
pressed solely GFP protein (27 kD) (Figure 1A). In addition, 
Bxpc-3 also showed endogenous WT K-ras expression  
(21 kD), and overexpressed K-Ras-GFP fusion protein did 
not seem to change the expression of endogenous K-Ras. 
 
Figure 1 (color online)  Expression of K-RAS-pAcGFP1-C3 in Bxpc-3 
cells and growth curves of Bxpc-3-derived clones expressing different 
types of K-ras gene. A, Protein expression of K-Ras-GFP (48 kD), GFP 
(27 kD), K-Ras (21 kD) and β-Actin (42 kD) in stable transfected Bxpc-3 
cells by Western blot. Densitometric analysis was made by AlphaEaseFC. 
B, Growth curve of Bxpc-3/vector clone expressing an empty vector (■), 
Bxpc-3/Wild type K-Ras (□), Bxpc-3/G12V K-Ras (▲), Bxpc-3/G12R 
K-Ras (ᇞ), Bxpc-3/G12D K-Ras (●), and Bxpc-3/G13D K-Ras (○). 
The vector transfected cells grew a little faster than the 
K-Ras-pAcGFP1-C3 transfected cells. In all five picked 
K-ras overexpressed clones, the K-Ras (G13D)-pAcGFP1- 
C3 transfected cells grew slower than all the other clones. In 
addition, the WT and other mutant clones showed compara-
ble in vitro growth (Figure 1B).  
2.2  Drug sensitivities of chemotherapy agents in 
Bxpc-3 derived clones expressing different K-ras muta-
tions  
MTT assay was performed to determine the role of K-ras 
mutation on the sensitivities of chemotherapy agents. For 
the EGFR tyrosine kinase inhibitors (EGFR-TKIs), the ex-
pression of mutant K-ras was associated with obvious re-
sistance to gefitinib, while showed no reduced sensitivity to 
erlotinib (Figure 2A and B). For the cytotoxic agents, the 
mutant clones showed obvious resistance to gemcitabine, 
5-FU, and docetaxel compared with the WT clone (Figure 
2C–E), whereas the response to cisplatin was not changed 
(Figure 2F). Moreover, the expression of a specific K-ras
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Figure 2  Cell survival of anti-cancer drugs in Bxpc-3-derived clones expressing different types of K-Ras gene. Cells were treated with erlotinib (A), ge-
fitinib (B), gemcitabine (C), 5-FU (D), cisplatin (E), and docetaxel (F) at the indicated drug concentrations. Data are presented as mean±SD of three inde-
pendent experiments. *, P<0.05 vs. WT clone and the difference of cell survival >20%. #, P<0.05 between the two indicated groups and the difference of cell 
survival >20%. 
mutation induced a different drug sensitivity pattern. Spe-
cifically, the expression of G13D was associated with a 
strong resistance to gemcitabine and docetaxel, whereas the 
expression of G12V resulted in a remarkably reduced re-
sponse to gefitinib and 5-FU. 
 
2.3  Apoptosis analysis of chemotherapy agents in 
Bxpc-3 derived clones expressing different K-ras muta-
tions  
To determine whether apoptotic cell death is responsible for 
the reduced sensitivity to gefitinib, 5-FU, and docetaxel, we 
performed flow cytometry analysis with Annexin V and PI 
staining. Cells were treated with gefitinib (20 µmol L1), 
5-FU (10 µmol L1), and docetaxel (0.01 µmol L1) for 48 h. 
The results showed that the apoptosis rate of gefitinib in 
K-ras G12D clone was significantly decreased compared 
with the WT clone, while the apoptosis rate of 5-FU was 
obviously lower in K-ras G12V clone (Figure 3). In addi-
tion, the induction of apoptosis by docetaxel was reduced in 
both G12V and G12D mutant cells. These results suggested 
that the sensitivity to chemotherapy agents was reduced in 
K-ras mutant cells mainly by decreasing induced tumor 
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Figure 3  Annexin V and PI staining for apoptosis assay in WT, G12D, and G12V clones after 48 treatment with gefitinib, 5-FU, and docetaxel. A, Apop-
tosis was assayed by Annexin V and PI staining and fluorescence-activated cell sorting analysis. B, The percentage of early and late apoptotic cells was 
indicated in the histogram. *, P<0.05 vs. WT clone. 
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cell apoptosis. 
2.4  K-Ras downstream signaling in Bxpc-3-derived 
clones expressing different K-ras mutations 
To determine if the overexpression of K-Ras can activate its 
downstream signaling, we analyzed the levels of p-Akt and 
p-Erk using Western blot. As shown by the results, the rela-
tive expression of p-Akt was up-regulated in K-ras G12V 
clone, while the levels of p-Erk was significantly higher in 
K-ras G12V, G12R and G12D clones (Figure 4). 
3  Discussion 
K-ras oncogene mutation is present in 90% pancreatic ade-
nocarcinoma, but its role in the response of chemotherapy 
agents is unclear. In this study, we generated K-Ras over-
expressing clones with the four most common amino acid 
substitutions (G12D, G12R, G12V and G13D) from the 
human pancreatic cancer cell line Bxpc-3 with a WT egfr 
and K-ras. Except for the K-ras (G13D) clone, the other 
mutant clones and WT clone showed similar in vitro 
growth.  
As expected, the expression of mutant K-ras induced an 
excessive activation of downstream signals p-Akt and p-Erk. 
Specifically, expression of G12V mutant K-ras resulted in 
activation of p-Akt, while the K-ras G12V, G12R, and 
G12D clones showed obvious up-regulation of p-Erk than 




Figure 4  Western blot analysis of K-Ras downstream signaling in 
Bxpc-3-derived clones expressing different types of K-ras gene. Densi-
tometry quantification was made by AlphaEaseFC. *, P<0.05 vs. WT 
clone. 
transfected cancer cell lines. Toulany et al. [16] reported 
that overexpression of G12V mutant K-ras strongly en-
hanced Akt phosphorylation in human breast cancer SKBr3 
cells. Similarly, Minjgee et al. [17] reported that transfec-
tion of G12V mutant K-ras not only increased the expres-
sion of p-Akt, but also enhanced Erk phosphorylation in 
head-and-neck cancer FaDu cells. Moreover, expression of 
G12D mutant K-ras was reported to be able to promote ac-
tivating of both PI3K and Erk activities in human pancreatic 
E6/E7/st cells [18]. Further, the present study also revealed 
the differences in the downstream activation by different 
types of K-ras mutation in human pancreatic Bxpc-3 cells.  
Recent clinical studies have suggested that the K-ras 
mutation may be a negative predictor of response to the 
anti-EGFR monoclonal antibody in colorectal cancer, but 
the influence of K-ras mutations on the therapeutic efficacy 
of EGFR-TKIs is still debating. In the present study, the 
sensitivity to gefitinib was reduced in K-ras G12V and 
G12D mutant Bxpc-3 clones compared with WT clone, 
while the response to erlotinib was not influenced by K-ras 
mutation. Gefitinib and erlotinib are both reversibly com-
petitive inhibitors of the tyrosine kinase domain of EGFR, 
but the present study implied the difference in the an-
ti-cancer effects between the two EGFR-TKIs. The re-
sistance to gefitinib in G12V and G12D clones may be 
partly explained by the excessive activation of K-Ras 
downstream signaling p-Akt and/or p-Erk. However, the 
phosph-Erk was also up-regulated in G12R clone, but the 
sensitivity to gefitinib was not changed. Therefore, the exact 
mechanism for the difference in the sensitivity to gefitinib 
in different types of K-ras mutant cells may warrant further 
study. 
In our study, we also compared the sensitivity to the cy-
totoxic agents in WT or different mutant clones. Compared 
with the WT clone, drug resistance to gemcitabine was ob-
served in the G13D clone, while the reduced sensitivity to 
5-FU and docetaxel was found in the G12V, G12D, and 
G13D clones. However, there was no influence of K-ras 
mutation on the response to cisplatin. This phenomenon 
may be partly due to the increased phosph-Akt and/or 
phosph-Erk in mutant clones. As Baneriee et al. [19] re-
ported, the reduction in p-Erk contributed to the reduced 
sensitivity of pancreatic ductal adenocarcinoma (PDAC) to 
gemcitabine. Over-expressed p-Erk was also reported to 
enhance the drug resistance to 5-FU [20] and docetaxel [21]. 
More interestingly, the expression of a specific K-ras muta-
tion induced a different sensitivity pattern to 5-FU, docet-
axel and gemcitabine in Bxpc-3 cells. Specifically, the 
G13D mutant clone showed a strong resistance to gemcita-
bine, 5-FU and docetaxel. Additionally, the expression of 
G12V and G12D mutant K-ras was associated with a re-
markably reduced response to 5-FU and docetaxel. The 
Annexin V/PI staining assay also demonstrated that the 
apoptosis of 5-FU, and docetaxel was also reduced in K-ras 
G12D and G12V clones. Previous study also demonstrated 
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that different types of K-ras mutation could also affect drug 
sensitivity in non-small-cell lung cancer cells [22]. But the 
response pattern to cisplatin and gemcitabine in non-small- 
cell lung cancer was different from the pattern in pancreatic 
cancer. The relationship between K-ras mutation and 
chemotherapy response may be different depending on tu-
mor types, which needs further investigation.  
In conclusion, we successfully constructed the recombi-
nant eukaryotic expression plasmids containing different 
types of mutant K-ras genes. The mutant K-ras genes were 
stably expressed in Bxpc-3 cells. Expression of mutant 
K-ras significantly reduced the sensitivity of Bxpc-3 cells to 
gefitinib, 5-FU, docetaxel and gemcitabine, whereas 
showed no effect on erlotinib and cisplatin. More interest-
ingly, different types of K-ras mutations could lead to a 
different pattern of drug sensitivity. Our study has provided 
preliminary data for further investigation on the effect of 
different K-ras mutations on the clinical efficacy of 
chemotherapeutic agents in pancreatic cancer. This may be 
important for the selection of effective clinical treatment.  
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